Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenoptin to Increase Phenylalanine Tolerance in PKU Children
NCT00272792Phase 3Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Feb 2006
- Modality
- Allosteric Modulators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in phenylketonuria (PKU) comparing Sapropterin Dihydrochloride with Placebo (2 arms). Primary endpoint: Amount of Dietary Supplemented Phenylalanine (Phe) Tolerated at Week 10. Started Feb 2006; status: completed.
02
Drugs
sapropterin
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT00272792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00272792.